Investment Thesis
Adagio Medical is in severe financial distress with zero revenue, negative stockholders' equity of -$1.3M, and substantial operating losses of -$17.8M. The company is burning cash at an unsustainable rate with negative free cash flow of -$15.7M, while carrying $21.2M in long-term debt against only $4.7M in cash, indicating imminent liquidity crisis.
Strengths
- Maintains $4.7M cash position providing short-term runway
- Medical device sector has growth potential if company survives
- Recent insider activity suggests management engagement despite challenges
Risks
- Zero revenue indicates complete failure to commercialize products or generate market acceptance
- Negative stockholders' equity of -$1.3M represents technical insolvency
- Negative free cash flow of -$15.7M with only $4.7M cash means 3-4 months of runway at current burn rate
- Current ratio of 0.84x and quick ratio of 0.68x indicate inability to meet short-term obligations
- $21.2M long-term debt burden with no revenue stream to service debt
- ROA of -69% demonstrates severe asset inefficiency and value destruction
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Progress toward revenue generation or product commercialization
- Debt restructuring or refinancing activities
- Changes in stockholders' equity trajectory
- Operating expense reduction initiatives
Financial Metrics
Revenue
0.0
Net Income
-21.8M
EPS (Diluted)
$-1.42
Free Cash Flow
-15.7M
Total Assets
31.5M
Cash
4.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-69.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.84x
Quick Ratio
0.68x
Debt/Equity
N/A
Debt/Assets
104.2%
Interest Coverage
N/A
Long-term Debt
21.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T12:22:11.649133 |
Data as of: 2025-09-30 |
Powered by Claude AI